Interpace OTC Stock Today

IDXG
 Stock
  

USD 1.43  0.12  7.74%   

Market Performance
0 of 100
Odds Of Distress
Over 80
Interpace Biosciences is trading at 1.43 as of the 1st of December 2022, a -7.74 percent down since the beginning of the trading day. The stock's lowest day price was 1.43. Interpace Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Interpace Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2022 and ending today, the 1st of December 2022. Click here to learn more.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. The company has 4.17 M outstanding shares of which 47.35 K shares are currently shorted by private and institutional investors with about 0.19 trading days to cover. More on Interpace Biosciences

Moving against Interpace Biosciences

-0.61JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr

Interpace Biosciences OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Interpace Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Interpace Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Interpace Biosciences generated a negative expected return over the last 90 days
Interpace Biosciences has high historical volatility and very poor performance
Interpace Biosciences may become a speculative penny stock
Interpace Biosciences has a very high chance of going through financial distress in the upcoming years
The company currently holds 16.03 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 40.05 M. Net Loss for the year was (13.29 M) with profit before overhead, payroll, taxes, and interest of 17.95 M.
Interpace Biosciences currently holds about 1.86 M in cash with (6.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Interpace Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 28.0% of Interpace Biosciences shares are held by company insiders
Latest headline from news.google.com: Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern - Yahoo Finance
CEOJack CPA
Average Analyst Recommendation
Analysts covering Interpace Biosciences report their recommendations after researching Interpace Biosciences' financial statements, talking to executives and customers, or listening in on Interpace Biosciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Interpace Biosciences. The Interpace consensus assessment is calculated by taking the average forecast from all of the analysts covering Interpace Biosciences.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Interpace Biosciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldOvervalued
Financial Strength
Interpace Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Interpace Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Interpace Biosciences' financial leverage. It provides some insight into what part of Interpace Biosciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Interpace Biosciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Interpace Biosciences deploys its capital and how much of that capital is borrowed.
Liquidity
Interpace Biosciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 16.03 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(22.37 Million)
Interpace Biosciences [IDXG] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with current market capitalization of 6.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Interpace Biosciences's market, we take the total number of its shares issued and multiply it by Interpace Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Interpace Biosciences conducts business under Healthcare sector and is part of Diagnostics & Research industry. The entity has 4.17 M outstanding shares of which 47.35 K shares are currently shorted by private and institutional investors with about 0.19 trading days to cover. Interpace Biosciences currently holds about 1.86 M in cash with (6.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Interpace Biosciences Probability Of Bankruptcy
Ownership
Interpace Biosciences secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.

Ownership Allocation (%)

Check Interpace Ownership Details

Interpace Stock Price Odds Analysis

What are Interpace Biosciences' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Interpace Biosciences jumping above the current price in 90 days from now is under 95%. The Interpace Biosciences probability density function shows the probability of Interpace Biosciences otc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Interpace Biosciences has a beta of 0.3932. This usually indicates as returns on the market go up, Interpace Biosciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Interpace Biosciences will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Interpace Biosciences is significantly underperforming NYSE Composite.
  Odds Below 1.43HorizonTargetOdds Above 1.43
5.71%90 days
 1.43 
94.26%
Based on a normal probability distribution, the odds of Interpace Biosciences to move above the current price in 90 days from now is under 95 (This Interpace Biosciences probability density function shows the probability of Interpace OTC Stock to fall within a particular range of prices over 90 days) .

Interpace Biosciences Historical Income Statement

Interpace Biosciences Income Statement is one of the three primary financial statements used for reporting Interpace's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Interpace Biosciences revenue and expense. Interpace Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Interpace Biosciences Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 23.37 Million. The current year Interest Expense is expected to grow to about 718.9 K, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to (16.3 M). View More Fundamentals

Interpace Stock Against Markets

Picking the right benchmark for Interpace Biosciences otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Interpace Biosciences otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Interpace Biosciences is critical whether you are bullish or bearish towards Interpace Biosciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Interpace Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

Interpace Biosciences Corporate Directors

Interpace Biosciences corporate directors refer to members of an Interpace Biosciences board of directors. The board of directors generally takes responsibility for the Interpace Biosciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Interpace Biosciences' board members must vote for the resolution. The Interpace Biosciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Kapila Ratnam - DirectorProfile
Heinrich Dreismann - DirectorProfile
Eric Lev - Non-Executive DirectorProfile
Harry Glorikian - DirectorProfile

Invested in Interpace Biosciences?

The danger of trading Interpace Biosciences is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Interpace Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Interpace Biosciences. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Interpace Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for analysis

When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Please note, there is a significant difference between Interpace Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.